Publications by authors named "J S Economou"
Article Synopsis
- The objective of the review was to assess and enhance research training during surgical residency to better align with modern surgical education and academic demands.
- The research identified a significant gap in standardized research training across surgical programs, with dedicated scholarly activity proving beneficial for residents.
- Recommendations include establishing minimum standards and flexible training options to ensure future surgeons are well-prepared for academic practice.
Article Synopsis
- IL32 is produced by various immune cells and melanoma cells, playing a significant role in the tumor microenvironment.
- Significant IL32 expression is found in many melanoma cell lines, correlating with a dedifferentiated genetic signature and can be induced by proinflammatory cytokines TNFα and IFNγ.
- The regulation of IL32 expression is influenced by specific sequences in the gene's 5' upstream region, and its expression is associated with T cell infiltration and treatment resistance in melanoma.
A promising arsenal of targeted and immunotherapy treatments for metastatic melanoma has emerged over the last decade. With these therapies, we now face new mechanisms of tumor-acquired resistance. We report here a patient whose metastatic melanoma underwent dedifferentiation as a resistance mechanism to adoptive T-cell transfer therapy (ACT) to the MART1 antigen, a phenomenon that had been observed only in mouse studies to date.
View Article and Find Full Text PDFAdoptive cell therapy (ACT) consisting of genetically engineered T cells expressing tumor antigen-specific T-cell receptors displays robust initial antitumor activity, followed by loss of T-cell activity/persistence and frequent disease relapse. We characterized baseline and longitudinal T-cell phenotype variations resulting from different manufacturing and administration protocols in patients who received ACT. Patients with melanoma who enrolled in the F5-MART-1 clinical trial (NCT00910650) received infusions of MART-1 T-cell receptors transgenic T cells with MART-1 peptide-pulsed dendritic cell vaccination.
View Article and Find Full Text PDF